The Journal of Korean Medicine (대한한의학회지)

The Society of Korean Medicine (대한한의학회)
권호 표지
DOI QR코드

DOI QR Code

Lonicerae Flos Inhibits Cigarette-induced Lung Inflammatory Responses in Animal Model of Chronic Obstructive Pulmonary Disease

  • Jung, Kyung-Hwa (Department of Physiology, College of Korean Medicine, Kyung Hee University) ;
  • Lee, Kye Seok (Department of Physiology, College of Korean Medicine, Kyung Hee University) ;
  • Kim, Youngeun (Department of Physiology, College of Korean Medicine, Kyung Hee University) ;
  • Park, Soojin (Department of Physiology, College of Korean Medicine, Kyung Hee University) ;
  • Hong, Moochang (Department of Physiology, College of Korean Medicine, Kyung Hee University) ;
  • Shin, Minkyu (Department of Physiology, College of Korean Medicine, Kyung Hee University) ;
  • Bae, Hyunsu (Department of Physiology, College of Korean Medicine, Kyung Hee University)
  • Received : 2013.04.09
  • Accepted : 2013.05.27
  • Published : 2013.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: In the present study, we evaluate the anti-inflammatory effect of Lonicerae Flos on cigarette-induced lung inflammatory responses in animal model of chronic obstructive pulmonary diseases (COPD). Methods: To inspect the effects of Lonicerae Flos, we evaluated Lonicerae Flos functions in vivo including immune cell profiles in bronchoalveolar lavage (BAL) fluid, cytokine production and tissue morphological changes. Results: Lonicerae Flos significantly inhibited immune cell infiltrations into the BAL fluid (neutrophils, macrophages, lymphocytes). TNF-${\alpha}$, and interleukin-6 (IL-6) were substantially decreased in the BAL fluid of Lonicerae Flos-treated mice compared with cigarette-exposed control mice. In addition, the hypertrophy of goblet cells in the epithelial cells was reduced in both Lonicerae Flos- and roflumilast-treated mice. Conclusions: The results of this study provide evidence that treatment with Lonicerae Flos exerts strong therapeutic effects against cigarette-induced lung inflammation in vivo. Therefore, this herbal medicine may represent a novel therapeutic agent for lung inflammation in general, as well as a specific agent for the treatment of COPD.

Keywords

References

  1. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523-32. https://doi.org/10.1183/09031936.06.00124605
  2. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183-92. https://doi.org/10.1038/nri2254
  3. Fabbri L, Pauwels RA, Hurd SS. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary updated 2003. COPD. 2004;1(1):105-41; discussion 3-4. https://doi.org/10.1081/COPD-120030163
  4. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532-55. https://doi.org/10.1164/rccm.200703-456SO
  5. Pesci A, Balbi B, Majori M, Cacciani G, Bertacco S, Alciato P, et al. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J. 1998;12(2):380-6. https://doi.org/10.1183/09031936.98.12020380
  6. Vlahos R, Bozinovski S, Chan SP, Ivanov S, Linden A, Hamilton JA, et al. Neutralizing gran ulocyte/macrophage colony-stimulating factor in hibits cigarette smoke-induced lung inflammation. Am J Respir Crit Care Med. 2010;182(1):34-4 https://doi.org/10.1164/rccm.200912-1794OC
  7. Betsuyaku T, Hamamura I, Hata J, Takahashi H, Mitsuhashi H, Adair-Kirk TL, et al. Bronchiolar chemokine expression is different after single versus repeated cigarette smoke exposure. Respir Res. 2008;9:7. https://doi.org/10.1186/1465-9921-9-7
  8. Boswell-Smith V, Spina D. PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast. Int J Chron Obstruct Pulmon Dis. 2007;2(2):121-9.
  9. Rabe KF, Tenor H, Dent G, Schudt C, Liebig S, Magnussen H. Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization. Am J Physiol. 1993;264(5 Pt 1):L458-64.
  10. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001;297(1):267-79.
  11. Kumar RK, Herbert C, Thomas PS, Wollin L, Beume R, Yang M, et al. Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J Pharmacol Exp Ther. 2003;307(1):349-55. https://doi.org/10.1124/jpet.103.053819
  12. Raouraoua-Boukari R, Sami-Merah S, Hammoudi-Triki D, Martin-Eauclaire MF, Laraba-Djebari F. Immunomodulation of the inflammatory response induced by Androctonus australis hector neurotoxins: biomarker interactions. Neuroimmunomodulation. 2012;19(2):103-10. https://doi.org/10.1159/000330241
  13. George J, Ioannides-Demos LL, Santamaria NM, Kong DC, Stewart K. Use of complementary and alternative medicines by patients with chronic obstructive pulmonary disease. Med J Aust. 2004;181(5):248-51.
  14. Lee H, Lee D, Kim Y, Lee G, Kim S-J, Jung S, et al. Lipopolysaccharide-induced lung inflammation is inhibited by Lonicera japonica Mol Cell Toxicol. 2011;7(1):87-93 https://doi.org/10.1007/s13273-011-0012-2
  15. Park E, Kum S, Wang C, Park SY, Kim BS, Schuller-Levis G. Anti-inflammatory activity of herbal medicines: inhibition of nitric oxide production and tumor necrosis factor-alpha secretion in an activated macrophage-like cell line. Am J Chin Med. 2005;33(3):415-24. https://doi.org/10.1142/S0192415X05003028
  16. Xagorari A, Papapetropoulos A, Mauromatis A, Economou M, Fotsis T, Roussos C. Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J Pharmacol Exp Ther. 2001;296(1):181-7.
  17. Choi JM, Ahn MH, Chae WJ, Jung YG, Park JC, Song HM, et al. Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation. Nat Med. 2006;12(5):574-9. https://doi.org/10.1038/nm1385
  18. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370(9589):765-73. https://doi.org/10.1016/S0140-6736(07)61380-4
  19. Kim D, You B, Lim H, Lee SJ. Toll-like receptor 2 contributes to chemokine gene expression and macrophage infiltration in the dorsal root ganglia after peripheral nerve injury. Mol Pain. 2011;7:74. https://doi.org/10.1186/1744-8069-7-74
  20. Stampfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol. 2009;9(5):377-84. https://doi.org/10.1038/nri2530
  21. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009;360(23):2445-54. https://doi.org/10.1056/NEJMra0804752
  22. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4:435-59. https://doi.org/10.1146/annurev.pathol.4.110807.092145
  23. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science. 1997;277(5334):2002-4. https://doi.org/10.1126/science.277.5334.2002
  24. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, et al. Optimal assessment and management of chronic obstructive pulmon ary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995;8(8):1398-420. https://doi.org/10.1183/09031936.95.08081398
  25. Page CP, Spina D. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handb Exp Pharmacol. 2011(204):391-414.
  26. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685-94. https://doi.org/10.1016/S0140-6736(09)61255-1
  27. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005;366(9485):563-71. https://doi.org/10.1016/S0140-6736(05)67100-0
  28. Blanc PD, Trupin L, Earnest G, Katz PP, Yelin EH, Eisner MD. Alternative therapies among adults with a reported diagnosis of asthma or rhinosinusitis: data from a population-based survey. Chest. 2001;120(5):1461-7. https://doi.org/10.1378/chest.120.5.1461
  29. Clark CE, Arnold E, Lasserson TJ, Wu T. Herbal interventions for chronic asthma in adults and children: a systematic review and meta-analysis. Prim Care Respir J. 2010;19(4):307-14. https://doi.org/10.4104/pcrj.2010.00041
  30. Puljic R, Benediktus E, Plater-Zyberk C, Baeue rle PA, Szelenyi S, Brune K, et al. Lipopolysacc haride-induced lung inflammation is inhibited by neutralization of GM-CSF. Eur J Pharmacol. 200 7;557(2-3):230-5. https://doi.org/10.1016/j.ejphar.2006.11.023
  31. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J Suppl. 2001;34:50s-9s.
  32. Mukhopadhyay S, Hoidal JR, Mukherjee TK. Ro le of TNFalpha in pulmonary pathophysiology. Respir Res. 2006;7:125. https://doi.org/10.1186/1465-9921-7-125
  33. Chen CY, Peng WH, Tsai KD, Hsu SL. Luteolin suppresses inflammation-associated gene expression by blocking NF-kappaB and AP-1 activation pathway in mouse alveolar macrophages. Life Sci. 2007;81(23-24):1602-14. https://doi.org/10.1016/j.lfs.2007.09.028

Cited by

  1. 만성폐쇄성폐질환 동물모델에 대한 射干湯 및 구성약물의 효과 vol.23, pp.2, 2015, https://doi.org/10.14374/hfs.2015.23.2.171